The latest seven-year data for QDENGA show continued protection against dengue infection (Representative image) NEW DELHI: India has approved its first dengue vaccine, with the Drug Controller General of India (DCGI) granting market authorisation to vaccine QDENGA, developed by Takeda Biopharmaceuticals India. The vaccine is approved for people aged 4 to 60 years and can be given regardless of whether a person has previously been infected with dengue.Unlike some dengue vaccines, QDENGA does not require pre-vaccination screening, allowing eligible individuals to receive the vaccine without first being tested for past dengue infection.Takeda said the approval marks a major step in India’s fight against dengue, a mosquito-borne disease that affects millions of people every year.”Since its launch in 2022, QDENGA has been approved in 43 countries, with more than 32 million doses distributed globally. This approval marks an important step forward in strengthening dengue prevention in India,” said Mahender Nayak, Head of Intercontinental Markets at Takeda.The company said long-term data collected over seven years showed that the vaccine continues to protect against dengue infection and hospitalisation caused by all four dengue virus serotypes.The Indian approval is based on findings from Takeda’s global clinical development programme, which included 19 Phase I, II and III clinical trials involving more than 28,000 participants in countries where dengue is common as well as regions where it is not.The decision was also supported by results from the Phase III DEN-302 clinical trial conducted in India, which assessed the vaccine’s safety and immune response in people between 4 and 60 years of age.QDENGA is given as two injections of 0.5 ml, administered under the skin three months apart.Takeda said India carries one of the world’s highest dengue burdens, with all four virus serotypes circulating simultaneously in several parts of the country.”QDENGA is designed to protect against all four serotypes, regardless of prior exposure. Its approval represents an important step in strengthening India’s comprehensive approach to dengue prevention, alongside vector control, surveillance, community awareness and other public health measures,” said Goh Choo Beng, Medical Affairs Head for Takeda’s Southeast Asia and India Cluster.The company added that the World Health Organization (WHO) recommends QDENGA for use in dengue-endemic regions and supports its inclusion in public immunisation programmes in high-transmission areas without requiring pre-vaccination screening.QDENGA has also received WHO prequalification, confirming that it meets international standards for quality, safety and effectiveness. This also makes the vaccine eligible for procurement by global agencies such as UNICEF and the Pan American Health Organization (PAHO).Dengue is a mosquito-borne viral disease reported in more than 125 countries. According to the company, India accounts for nearly one-third of the global dengue burden, with rapid urbanisation, climate change and widespread mosquito breeding continuing to increase the risk of infection across the country.Get the latest India News and Live updates. Download the TOI app.About the AuthorTOI News DeskThe TOI News Desk comprises a dedicated and tireless team of journalists who operate around the clock to deliver the most current and comprehensive news and updates to the readers of The Times of India worldwide. With an unwavering commitment to excellence in journalism, our team is at the forefront of gathering, verifying, and presenting breaking news, in-depth analysis, and insightful reports on a wide range of topics. The TOI News Desk is your trusted source for staying informed and connected to the ever-evolving global landscape, ensuring that our readers are equipped with the latest developments that matter most.”Read MoreEnd of ArticleFollow Us On Social MediaVideosDelhi Metro Closes Five Stations, Police Block CJP’s Parliament March Amid Massive SecurityCentre To Introduce Bill Making Insult To Vande Mataram A Criminal OffenceDelhi Police Warns Against CJP’s Parliament March; Says No Permission Granted, Legal Action Likely’Strictly Prohibited’: Delhi Police Invokes Section 163, Issues Warning Over CJP’s Sansad MarchCJP Releases Do’s & Don’ts For ‘Chalo Sansad’ March As Sonam Wangchuk Continues Hunger StrikeFlash Floods, Landslides Hit J&K’s Poonch-Rajouri; Vaishno Devi, Amarnath Yatra SuspendedModi Govt’s Invitation To Rebel TMC Faction Sparks Row, Oppn Walks Out Of All-Party Meet‘Entire System Shakes When…’: Jantar Mantar Protesters Speak Ahead Of July 20 Sansad MarchTrump Administration Tightens F-1 Visa Rules; 4-Year Stay Limit, Shorter Grace PeriodRahul Gandhi, Kharge Seek Independent Probe Into Ram Mandir Donation Theft Allegations123PhotostoriesInspired by UK homes: Here are 6 kitchen worktop ideas to tryStop throwing potato peels and combine them with baking soda: 5 clever kitchen uses you’ll wish you knew earlierThe Most Unexpected Zodiac Pairings That Actually Work12 popular South Indian dosas and their calories per servingDoctor warns these 7 everyday habits can shorten your health span after 50, most people ignore themFrom Porcelain Bears to Leather Fish: The weird luxury fashion trend everyone’s talking aboutYour skin may be reflecting your gut health: Doctor explains why acne, eczema, and rosacea could begin in the digestive systemWhich Zodiac Signs Have the Warmest Hearts?”My three go-to pre- and post-workout snacks are…”: Japan Open 2026 winner PV Sindhu reveals her energy-boosting diet‘Ramayana’ trailer event in Delhi: What Ranbir Kapoor, Sai Pallavi, Rakul Preet and the star cast wore123Hot PicksDU BTech AdmissionAP EAPCET counsellingUS import pricesBihar DCECE round 2 seat allotmentDelhi Metro stationsJantar MantarISRO scientists resignMahadev betting appSkyroot AerospaceTop TrendingRajasthan RapeLucknow Jawahar Bhawan FireWeather TomorrowCJP ProtestSonam WangchukNEET Paper LeakJoseph VijayAbhishek BanerjeeIshowspeedIran war

The latest seven-year data for QDENGA show continued protection against dengue infection (Representative image) NEW DELHI: India has approved its first dengue vaccine, with the Drug Controller General of India (DCGI) granting market authorisation to vaccine QDENGA, developed by Takeda Biopharmaceuticals India. The vaccine is approved for people aged 4 to 60 years and can be given regardless of whether a person has previously been infected with dengue.Unlike some dengue vaccines, QDENGA does not require pre-vaccination screening, allowing eligible individuals to receive the vaccine without first being tested for past dengue infection.Takeda said the approval marks a major step in India’s fight against dengue, a mosquito-borne disease that affects millions of people every year.”Since its launch in 2022, QDENGA has been approved in 43 countries, with more than 32 million doses distributed globally. This approval marks an important step forward in strengthening dengue prevention in India,” said Mahender Nayak, Head of Intercontinental Markets at Takeda.The company said long-term data collected over seven years showed that the vaccine continues to protect against dengue infection and hospitalisation caused by all four dengue virus serotypes.The Indian approval is based on findings from Takeda’s global clinical development programme, which included 19 Phase I, II and III clinical trials involving more than 28,000 participants in countries where dengue is common as well as regions where it is not.The decision was also supported by results from the Phase III DEN-302 clinical trial conducted in India, which assessed the vaccine’s safety and immune response in people between 4 and 60 years of age.QDENGA is given as two injections of 0.5 ml, administered under the skin three months apart.Takeda said India carries one of the world’s highest dengue burdens, with all four virus serotypes circulating simultaneously in several parts of the country.”QDENGA is designed to protect against all four serotypes, regardless of prior exposure. Its approval represents an important step in strengthening India’s comprehensive approach to dengue prevention, alongside vector control, surveillance, community awareness and other public health measures,” said Goh Choo Beng, Medical Affairs Head for Takeda’s Southeast Asia and India Cluster.The company added that the World Health Organization (WHO) recommends QDENGA for use in dengue-endemic regions and supports its inclusion in public immunisation programmes in high-transmission areas without requiring pre-vaccination screening.QDENGA has also received WHO prequalification, confirming that it meets international standards for quality, safety and effectiveness. This also makes the vaccine eligible for procurement by global agencies such as UNICEF and the Pan American Health Organization (PAHO).Dengue is a mosquito-borne viral disease reported in more than 125 countries. According to the company, India accounts for nearly one-third of the global dengue burden, with rapid urbanisation, climate change and widespread mosquito breeding continuing to increase the risk of infection across the country.Get the latest India News and Live updates. Download the TOI app.About the AuthorTOI News DeskThe TOI News Desk comprises a dedicated and tireless team of journalists who operate around the clock to deliver the most current and comprehensive news and updates to the readers of The Times of India worldwide. With an unwavering commitment to excellence in journalism, our team is at the forefront of gathering, verifying, and presenting breaking news, in-depth analysis, and insightful reports on a wide range of topics. The TOI News Desk is your trusted source for staying informed and connected to the ever-evolving global landscape, ensuring that our readers are equipped with the latest developments that matter most.”Read MoreEnd of ArticleFollow Us On Social MediaVideosDelhi Metro Closes Five Stations, Police Block CJP’s Parliament March Amid Massive SecurityCentre To Introduce Bill Making Insult To Vande Mataram A Criminal OffenceDelhi Police Warns Against CJP’s Parliament March; Says No Permission Granted, Legal Action Likely’Strictly Prohibited’: Delhi Police Invokes Section 163, Issues Warning Over CJP’s Sansad MarchCJP Releases Do’s & Don’ts For ‘Chalo Sansad’ March As Sonam Wangchuk Continues Hunger StrikeFlash Floods, Landslides Hit J&K’s Poonch-Rajouri; Vaishno Devi, Amarnath Yatra SuspendedModi Govt’s Invitation To Rebel TMC Faction Sparks Row, Oppn Walks Out Of All-Party Meet‘Entire System Shakes When…’: Jantar Mantar Protesters Speak Ahead Of July 20 Sansad MarchTrump Administration Tightens F-1 Visa Rules; 4-Year Stay Limit, Shorter Grace PeriodRahul Gandhi, Kharge Seek Independent Probe Into Ram Mandir Donation Theft Allegations123PhotostoriesInspired by UK homes: Here are 6 kitchen worktop ideas to tryStop throwing potato peels and combine them with baking soda: 5 clever kitchen uses you’ll wish you knew earlierThe Most Unexpected Zodiac Pairings That Actually Work12 popular South Indian dosas and their calories per servingDoctor warns these 7 everyday habits can shorten your health span after 50, most people ignore themFrom Porcelain Bears to Leather Fish: The weird luxury fashion trend everyone’s talking aboutYour skin may be reflecting your gut health: Doctor explains why acne, eczema, and rosacea could begin in the digestive systemWhich Zodiac Signs Have the Warmest Hearts?”My three go-to pre- and post-workout snacks are…”: Japan Open 2026 winner PV Sindhu reveals her energy-boosting diet‘Ramayana’ trailer event in Delhi: What Ranbir Kapoor, Sai Pallavi, Rakul Preet and the star cast wore123Hot PicksDU BTech AdmissionAP EAPCET counsellingUS import pricesBihar DCECE round 2 seat allotmentDelhi Metro stationsJantar MantarISRO scientists resignMahadev betting appSkyroot AerospaceTop TrendingRajasthan RapeLucknow Jawahar Bhawan FireWeather TomorrowCJP ProtestSonam WangchukNEET Paper LeakJoseph VijayAbhishek BanerjeeIshowspeedIran war


India approves its first dengue vaccine QDENGA after DCGI clearance
The latest seven-year data for QDENGA show continued protection against dengue infection (Representative image)

NEW DELHI: India has approved its first dengue vaccine, with the Drug Controller General of India (DCGI) granting market authorisation to vaccine QDENGA, developed by Takeda Biopharmaceuticals India. The vaccine is approved for people aged 4 to 60 years and can be given regardless of whether a person has previously been infected with dengue.Unlike some dengue vaccines, QDENGA does not require pre-vaccination screening, allowing eligible individuals to receive the vaccine without first being tested for past dengue infection.Takeda said the approval marks a major step in India’s fight against dengue, a mosquito-borne disease that affects millions of people every year.“Since its launch in 2022, QDENGA has been approved in 43 countries, with more than 32 million doses distributed globally. This approval marks an important step forward in strengthening dengue prevention in India,” said Mahender Nayak, Head of Intercontinental Markets at Takeda.The company said long-term data collected over seven years showed that the vaccine continues to protect against dengue infection and hospitalisation caused by all four dengue virus serotypes.The Indian approval is based on findings from Takeda’s global clinical development programme, which included 19 Phase I, II and III clinical trials involving more than 28,000 participants in countries where dengue is common as well as regions where it is not.The decision was also supported by results from the Phase III DEN-302 clinical trial conducted in India, which assessed the vaccine’s safety and immune response in people between 4 and 60 years of age.QDENGA is given as two injections of 0.5 ml, administered under the skin three months apart.Takeda said India carries one of the world’s highest dengue burdens, with all four virus serotypes circulating simultaneously in several parts of the country.“QDENGA is designed to protect against all four serotypes, regardless of prior exposure. Its approval represents an important step in strengthening India’s comprehensive approach to dengue prevention, alongside vector control, surveillance, community awareness and other public health measures,” said Goh Choo Beng, Medical Affairs Head for Takeda’s Southeast Asia and India Cluster.The company added that the World Health Organization (WHO) recommends QDENGA for use in dengue-endemic regions and supports its inclusion in public immunisation programmes in high-transmission areas without requiring pre-vaccination screening.QDENGA has also received WHO prequalification, confirming that it meets international standards for quality, safety and effectiveness. This also makes the vaccine eligible for procurement by global agencies such as UNICEF and the Pan American Health Organization (PAHO).Dengue is a mosquito-borne viral disease reported in more than 125 countries. According to the company, India accounts for nearly one-third of the global dengue burden, with rapid urbanisation, climate change and widespread mosquito breeding continuing to increase the risk of infection across the country.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *